A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Abstract The incidence of melanoma, the third most common skin cancer, has been on rise in recent years. In addition, it a high mortality rate due to its aggressiveness. Phototherapy, as promising treatment method, can effectively kill tumor cells, but is incapable metastasis. Herein, nanomaterial (TPC@OVA NPs) developed for phototherapy conjunction with immunotherapy against melanoma. TPC, derivative porphyrin, used photosensitizer excellent biosafety and photostability. After assembly ovalbumin (OVA), TPC@OVA NPs vaccine properties formed, which not only ablate primary also induce immunogenic cell death (ICD). DC cells be stimulated mature by exogenous OVA, enhancing immune response tumors further activating T lymphocytes. Combined checkpoint inhibitor aPD‐1, microenvironment reshaped, increased activity are validated. This work highlights potential combining

Language: Английский

---

Glioblastoma Cell Lysate and Adjuvant Nanovaccines via Strategic Vaccination Completely Regress Established Murine Tumors

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Abstract Tumor vaccines have shown great promise for treating various malignancies; however, glioblastoma (GBM), characterized by its immunosuppressive tumor microenvironment, high heterogeneity, and limited accessibility, has achieved only modest clinical benefits. Here, it is reported that GBM cell lysate nanovaccines boosted with TLR9 agonist CpG ODN (GlioVac) via a strategic vaccination regimen achieve complete regression of malignant murine tumors. Subcutaneous administration GlioVac promotes uptake cervical lymph nodes antigen presentation cells, bolstering cross‐presentation infiltration GBM‐specific CD8 + T cells into the tumor. Notably, involving two subcutaneous three intravenous vaccinations not activates systemic anti‐GBM immunity but also further enhances cytotoxic lymphocytes, effectively reshaping “cold” “hot” This approach led to state tumor‐free survival in 5 out 7 mice bearing established GL261 model protection from rechallenge. In an orthotopic hRas‐GBM induced lentiviral plasmid, resulted ≈100% regression. These findings suggest provides personalized therapeutic vaccine strategy glioblastoma.

Language: Английский

---

Arsenic trioxide: Therapeutic uses, environmental impact, and risk management

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 645 - 654

Published: Oct. 1, 2024

Language: Английский

---